Table 1 Baseline characteristics of responders and non-responders, split for treatment received
From: Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?
Item | ADA (n = 60) | ETN (n = 60) | ||||
|---|---|---|---|---|---|---|
| Â | Non-resp | Resp | p value | Non-resp | Resp | p value |
|  | (n = 30) | (n = 30) |  | (n = 30) | (n = 30) |  |
Female gender, n (%) | 21 (70) | 21 (70) | 1.00 | 25 (83) | 21 (70) | 0.36 |
Age, mean years ± sd | 54.4 ± 10.9 | 53.5 ± 12.7 | 0.76 | 58.3 ± 9.2 | 55.1 ± 10.5 | 0.22 |
Current smoker, n (%) | 16 (53) | 8 (27) | 0.06 | 8 (27) | 7 (23) | 1.00 |
RF positivity, n (%) | 16 (53) | 21 (70) | 0.29 | 20 (67) | 22 (73) | 0.78 |
ACPA positivity, n (%) | 19 (63) | 19 (63) | 1.00 | 19 (63) | 26 (87) | 0.07 |
CRP, mg/l median (IQR) | 5.2 (1.6–10.5) | 5.5 (2.0–12.3) | 0.78 | 4.0 (2.0–9.0) | 8.5 (4.0–18.3) | 0.03 |
No. of previously used bDMARDs | Â | Â | Â | Â | Â | 1.00 |
 0, n (%) | 20 (67) | 23 (78) |  | 22 (73) | 22 (73) |  |
 1, n (%) | 9 (30) | 7 (23) |  | 7 (23) | 7 (23) |  |
 2, n (%) | 1 (3) | 0 (0) |  | 1 (3) | 1 (3) |  |
Concomitant treatment, n (%) | 29 (97) | 29 (97) | 1.00 | 27 (90) | 29 (97) | 0.61 |
 MTX, n (%) | 21 (70) | 27 (90) | 0.10 | 18 (60) | 25 (83) | 0.08 |
 SSZ, n (%) | 2 (7) | 4 (13) | 0.67 | 4 (13) | 2 (7) | 0.67 |
 HCQ, n (%) | 8 (27) | 7 (23) | 1.00 | 10 (33) | 11 (37) | 1.00 |
 GC, n (%) | 15 (50) | 4 (13) | 0.01 | 11 (37) | 6 (20) | 0.25 |
Baseline DAS28, mean ± sd | 3.9 ± 1.4 | 4.7 ± 0.9 | 0.01 | 4.3 ± 1.2 | 4.6 ± 0.9 | 0.21 |
 TJC, median (IQR) | 5.0 (1.0–13.0) | 7.0 (4.0–14.3) | 0.35 | 6.5 (2.8–11.3) | 5.0 (2.8–11.3) | 0.87 |
 SJC, median (IQR) | 0.0 (0.0–4.0) | 2.0 (0.0–4.0) | 0.03 | 1.0 (0.0–3.3) | 2.0 (0.8–4.0) | 0.20 |
 VAS-GH, mean ± sd | 55.2 ± 23.8 | 63.8 ± 22.0 | 0.15 | 55.5 ± 22.8 | 55.1 ± 10.5 | 0.76 |
 ESR, median mm/hr (IQR) | 11.0 (3.8–26.0) | 16.5 (9.0–32.0) | 0.14 | 13.0 (5.8–33.8) | 21.0 (14.3–39.5) | 0.07 |